Effect of MDR1 haplotype on risk of Parkinson disease

Archives of Neurology

Volumn 62, Issue 3, 2005, Pages 460-464

  Tan, Eng King ^a,b,c   Chan, Daniel Kam Yin ^d   Ng, Ping Wing ^e   Woo, Jean ^f   Teo, Y Y ^g   Tang, Kun ^h   Wong, Li Peng ^h   Chong, Samuel S ^h,i   Tan, Chris ^a   Shen, Hui ^a   Zhao, Yi ^a   Lee, Caroline G L ^h,j  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^c Singapore Health Services   (Singapore)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j DIVISION OF MEDICAL ONCOLOGY   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ALLELE; ARTICLE; BLOOD BRAIN BARRIER; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DISEASE COURSE; ETHNOLOGY; EXON; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC RISK; HAPLOTYPE; HONG KONG; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENES, MDR; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 20044365400     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.3.460     Document Type: Article

References (26)

1. Jankovic J. Parkinson's disease: a half century of progress. Neurology. 2001;57 (suppl 3):S1-S3.
2. Dawson TM, Dawson VL. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest. 2003;111:145-151.
3. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology. 2000;55:533-538.
4. Tan EK, Chai A, Lum SY, et al. Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: a study in an Asian population. Am J Med Genet B Neuropsychiatr Genet. 2003;120:58-62.
5. Chan DK, Woo J, Ho SC, et al. Genetic and environmental risk factors of Parkinson's disease in a Chinese population. J Neurol Neurosurg Psychiatry. 1998; 65:781-784.
6. Tan EK, Chai A, Teo YY, et al. Alpha-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology. 2004;62:128-131.
7. Langston JW. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann Neurol. 1998;44(suppl 1):S45-S52.
8. Tan EK, Chai A, Zhao Y, et al. Mitochondrial complex I polymorphism and cigarette smoking in Parkinson's disease. Neurology. 2002;59:1288-1289.
9. Christensen PM, Gotzsche PC, Brosen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Pharmacogenetics. 1998;8:473-479.
10. Lee CG, Gottesman MM. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest. 1998;101:287-288.
11. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199.
12. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol. 2002;62:1-6.
13. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-3478.
14. Lee CG, Tang K, Cheung YB, et al. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese [letter]. J Med Genet. 2004; 41:e60.
15. Furuno T, Landi MT, Ceroni M, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics. 2002;12:529-534.
16. Drozdzik M, Bialecka M, Mysliwiec K, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics. 2003;13:259-263.
17. Phillips MS, Lawrence R, Sachidanandam R, et al. Chromosome-wide distribution of haplotype blocks and the role of recombination hot spots. Nat Genet. 2003; 33:382-387.
18. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
19. Gwee PC, Tang K, Chua JM, et al. Simultaneous genotyping of seven single nucleotide polymorphisms in the MDR1 gene by single-tube multiplex minisequencing. Clin Chem. 2003;49:672-676.
20. Tang K, Wong LP, Lee EJ, Chong SS, Lee CG. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet. 2004;13:783-797.
21. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491-502.
22. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97:2517-2524.
23. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998; 101:289-294.
24. Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001;11:293-298.
25. Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18:1400-1404.
26. Roberts R, Joyce P, Mulder R, et al. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated with major depression. Pharmacogenomics J. 2002;2:191-196.